Vyera Pharmaceuticals, LLC and five affiliates filed chapter 11, Subchapter V on May 9, 2023 (lead case 23-10605, D. Del.; Judge J. Kate Stickles). The confirmed restructuring used a dual-track structure: liquidation of legacy assets into the Vyera Liquidating Trust and preservation of optionality around Orpha Labs' ORL-101 program and potential FDA Priority Review Voucher (PRV) proceeds.
